{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 43,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide uses a horizontal bar chart format to compare treatment durations across different lines of therapy (2L+, 3L+, 4L+).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/25",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Comparison of treatment durations for chemotherapy, ET monotherapy, sacituzumab govitecan, and Enhertu.",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da670e9b-196c-41e8-a1a2-ca34f5159597",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.95,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "1. Sledge GW. et al., JAMA Oncol 2020.6(1) 116-124. 2. Giridhar GV., SABCS 2018 Abstract #P6-18-09. 3. Chainitikun S. et al., Breast Cancer Research and Treatment 2020. 4. Rossi L et al., Breast Cancer Res 21, 71(2019). 5. Turner NC. et al., 2018 Nov 15,379(30) 1925-1936. 6. Xi j. et al., JNCCN 2019. HR+ = hormone-receptor positive; RWE = real-world evidence; ET = endocrine therapy; CDK4/6i = cyclin-dependent kinase 4/6 inhibitors; MDACC = MD Anderson Cancer Center.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecefdb0e-4417-4e57-a2a6-cadb3abf4950",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Enhertu transforms the treatment paradigm for HR+ metastatic patients who see limited benefit from current standards of care",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5592eb26-a6c6-409f-8e2f-40f7ff8268c6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "d0dcc7c9-91ff-466e-8926-e88fe360601d",
      "evidence": "The slide compares multiple treatment options against a new standard (Enhertu) to demonstrate superiority.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}